Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1879 1
1881 2
1882 1
1969 1
1970 2
1971 1
1972 4
1974 1
1975 1
1976 2
1977 1
1978 2
1979 1
1981 1
1982 3
1983 5
1984 3
1985 4
1986 4
1988 1
1989 1
1992 1
1993 2
2000 1
2001 2
2003 1
2004 2
2005 3
2006 1
2007 1
2008 2
2009 6
2010 5
2011 5
2012 2
2013 4
2014 3
2015 3
2016 7
2017 3
2018 3
2019 4
2020 7
2021 10
2022 10
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. Among authors: boileau jf. N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651. N Engl J Med. 2022. PMID: 35139274 Clinical Trial.
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW, Afenjar K, Fresco R, Helms HJ, Xu J, Lin YG, Sparano J, Slamon D. Hurvitz SA, et al. Among authors: boileau jf. Lancet Oncol. 2018 Jan;19(1):115-126. doi: 10.1016/S1470-2045(17)30716-7. Epub 2017 Nov 23. Lancet Oncol. 2018. PMID: 29175149 Clinical Trial.
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.
Fehrenbacher L, Cecchini RS, Geyer CE Jr, Rastogi P, Costantino JP, Atkins JN, Crown JP, Polikoff J, Boileau JF, Provencher L, Stokoe C, Moore TD, Robidoux A, Flynn PJ, Borges VF, Albain KS, Swain SM, Paik S, Mamounas EP, Wolmark N. Fehrenbacher L, et al. Among authors: boileau jf. J Clin Oncol. 2020 Feb 10;38(5):444-453. doi: 10.1200/JCO.19.01455. Epub 2019 Dec 10. J Clin Oncol. 2020. PMID: 31821109 Free PMC article. Clinical Trial.
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Fasching PA, Afenjar K, Spera G, Lopez-Valverde V, Song C, Trask P, Boulet T, Sparano JA, Symmans WF, Thompson AM, Slamon D. Hurvitz SA, et al. Among authors: boileau jf. J Clin Oncol. 2019 Sep 1;37(25):2206-2216. doi: 10.1200/JCO.19.00882. Epub 2019 Jun 3. J Clin Oncol. 2019. PMID: 31157583 Free PMC article. Clinical Trial.
[Inherited primitive and secondary polycythemia].
Barba T, Boileau JC, Pasquet F, Hot A, Pavic M. Barba T, et al. Among authors: boileau jc. Rev Med Interne. 2016 Jul;37(7):460-5. doi: 10.1016/j.revmed.2015.12.022. Epub 2016 Jan 27. Rev Med Interne. 2016. PMID: 26827274 Review. French.
Acute Pulmonary Tuberculosis.
Boileau JP. Boileau JP. Br Med J. 1881 Mar 5;1(1053):337. doi: 10.1136/bmj.1.1053.337-a. Br Med J. 1881. PMID: 20749807 Free PMC article. No abstract available.
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.
Litton JK, Regan MM, Pusztai L, Rugo HS, Tolaney SM, Garrett-Mayer E, Amiri-Kordestani L, Basho RK, Best AF, Boileau JF, Denkert C, Foster JC, Harbeck N, Jacene HA, King TA, Mason G, O'Sullivan CC, Prowell TM, Richardson AL, Sepulveda KA, Smith ML, Tjoe JA, Turashvili G, Woodward WA, Butler LP, Schwartz EI, Korde LA. Litton JK, et al. Among authors: boileau jf. J Clin Oncol. 2023 Sep 20;41(27):4433-4442. doi: 10.1200/JCO.23.00435. Epub 2023 Jul 11. J Clin Oncol. 2023. PMID: 37433103 Free PMC article.
Epigenetic factors and autism spectrum disorders.
Flashner BM, Russo ME, Boileau JE, Leong DW, Gallicano GI. Flashner BM, et al. Among authors: boileau je. Neuromolecular Med. 2013 Jun;15(2):339-50. doi: 10.1007/s12017-013-8222-5. Epub 2013 Mar 7. Neuromolecular Med. 2013. PMID: 23468062 Review.
[Chronic hepatitis].
Meunier P, Boileau J, Mousseau R. Meunier P, et al. Among authors: boileau j. Union Med Can. 1978 Mar;107(3):299-305. Union Med Can. 1978. PMID: 345578 Review. French. No abstract available.
128 results